Witness Mapanga1,2, Shane A Norris1,3, Wenlong C Chen4,5, Charmaine Blanchard1,6, Anita Graham7, Laurel Baldwin-Ragaven8, Tom Boyles9,10,11, Bernard Donde12, Linda Greef13, Ken Huddle7, Busisiwe Khumalo7, Elizabeth Leepile14, Buhle Lubuzo15, Raynolda Makhutle1, Yusuf Mayet2, Merika Tsitsi7,16, Preethi Mistri17, Keletso Mmoledi1, Mpho Ratshikana-Moloko1,6, Rajen Morer7, Lauren Pretorius18, Jayshina Punwasi8, Guy A Richards7, Paul Ruff2, Dineo Shabalala2, Maureen Sibadela19, Nita Soma16, Michelle Wong7, Maureen Joffe1,3. 1. Division of the Wits Health Consortium, Non-Communicable Diseases Research (NCDR), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Division of Medical Oncology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. SAMRC/Wits Developmental Pathways to Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa. 5. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Centre for Palliative Care, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. 7. Division of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 8. Department of Family Medicine and Primary Care, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 9. Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng, South Africa. 10. ANOVA Health Institute, Johannesburg, South Africa. 11. London School of Hygiene and Tropical Medicine, London, United Kingdom. 12. Division Radiation Oncology, Department of Radiation Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 13. The Cancer Alliance, Johannesburg, South Africa. 14. Gauteng Department of Health, Tladi Provincial Clinic, Johannesburg, South Africa. 15. Discipline of Public Health Medicine, School of Nursing and Public Health, University of the KwaZulu Natal, Durban, South Africa. 16. Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. 17. CANSA Association South Africa, Johannesburg, South Africa. 18. Campaigning for Cancer, Johannesburg, South Africa. 19. Alpha World Ministries Social Care Centre, Johannesburg, South Africa.
Abstract
BACKGROUND: Lung cancer is the highest incident cancer globally and is associated with significant morbidity and mortality particularly if identified at a late stage. Poor patient outcomes in low- and middle-income countries (LMIC's) might reflect contextual patient and health system constraints at multiple levels, that act as barriers to prevention, disease recognition, diagnosis, and treatment. Lung cancer screening, even for high-risk patients, is not available in the public health sector in South Africa (SA), where the current HIV and tuberculosis (TB) epidemics often take precedence. Yet, there has been no formal assessment of the individual and health-system related barriers that may delay patients with lung cancer from seeking and accessing help within the public health care system and receiving the appropriate and effective diagnosis and treatment. This study aimed to derive consensus from health-system stakeholders in the urban Gauteng Province of SA on the most important challenges faced by the health services and patients in achieving optimum lung cancer management and to identify potential solutions. METHODS: The study was undertaken among 27 participant stakeholders representing clinical managers, clinicians, opinion leaders from the public health sector and non-governmental organisation (NGO) representatives. The study compromised two components: consensus and engagement. For the consensus component, the Delphi Technique was employed with open-ended questions and item ranking from five rounds of consensus-seeking, to achieve collective agreement on the most important challenges faced by patients and the health services in achieving optimal lung cancer management. For the engagement component, the Nominal Group Technique was used to articulate ideas and reach an agreement on the group's recommendations for solution strategies and approaches. RESULTS: Public health sector stakeholders suggested that a lack of knowledge and awareness of lung cancer, and the apparent stigma associated with the disease and its risk factors, as well as symptoms and signs, are critical to treatment delay. Furthermore, delays in up-referral of patients with suspected lung cancer from district health care level were attributed to inadequate knowledge arising from a lack of in-service training of nurses and doctors regarding oncologic symptoms, risk factors, need for further investigation, interpretation of x-rays and available treatments. At a tertiary level, participants suggested that insufficient availability of specialised diagnostic resources (imaging, cytological and pathological services including biomolecular assessment of lung cancer), theatres, cardiothoracic surgeons, and appropriate therapeutic modalities (chemotherapeutic agents and radiation oncology) are the main barriers to the provision of optimal care. It was suggested that a primary prevention programme initiated by the government that involves private-public partnerships may improve lung cancer management nationally. CONCLUSIONS: Considerable barriers to the early identification and treatment of lung cancer exist. Finding solutions to overcome both individual and health-system level obstacles to lung cancer screening and management are vital to facilitate early identification and treatment, and to improve survival. Furthermore, research on inexpensive biomarkers for asymptomatic disease detection, the introduction of diagnostic imaging tools that utilise artificial intelligence to compensate for inadequate human resources and improving clinical integration across all levels of the healthcare system are essential.
BACKGROUND:Lung cancer is the highest incident cancer globally and is associated with significant morbidity and mortality particularly if identified at a late stage. Poor patient outcomes in low- and middle-income countries (LMIC's) might reflect contextual patient and health system constraints at multiple levels, that act as barriers to prevention, disease recognition, diagnosis, and treatment. Lung cancer screening, even for high-risk patients, is not available in the public health sector in South Africa (SA), where the current HIV and tuberculosis (TB) epidemics often take precedence. Yet, there has been no formal assessment of the individual and health-system related barriers that may delay patients with lung cancer from seeking and accessing help within the public health care system and receiving the appropriate and effective diagnosis and treatment. This study aimed to derive consensus from health-system stakeholders in the urban Gauteng Province of SA on the most important challenges faced by the health services and patients in achieving optimum lung cancer management and to identify potential solutions. METHODS: The study was undertaken among 27 participant stakeholders representing clinical managers, clinicians, opinion leaders from the public health sector and non-governmental organisation (NGO) representatives. The study compromised two components: consensus and engagement. For the consensus component, the Delphi Technique was employed with open-ended questions and item ranking from five rounds of consensus-seeking, to achieve collective agreement on the most important challenges faced by patients and the health services in achieving optimal lung cancer management. For the engagement component, the Nominal Group Technique was used to articulate ideas and reach an agreement on the group's recommendations for solution strategies and approaches. RESULTS: Public health sector stakeholders suggested that a lack of knowledge and awareness of lung cancer, and the apparent stigma associated with the disease and its risk factors, as well as symptoms and signs, are critical to treatment delay. Furthermore, delays in up-referral of patients with suspected lung cancer from district health care level were attributed to inadequate knowledge arising from a lack of in-service training of nurses and doctors regarding oncologic symptoms, risk factors, need for further investigation, interpretation of x-rays and available treatments. At a tertiary level, participants suggested that insufficient availability of specialised diagnostic resources (imaging, cytological and pathological services including biomolecular assessment of lung cancer), theatres, cardiothoracic surgeons, and appropriate therapeutic modalities (chemotherapeutic agents and radiation oncology) are the main barriers to the provision of optimal care. It was suggested that a primary prevention programme initiated by the government that involves private-public partnerships may improve lung cancer management nationally. CONCLUSIONS: Considerable barriers to the early identification and treatment of lung cancer exist. Finding solutions to overcome both individual and health-system level obstacles to lung cancer screening and management are vital to facilitate early identification and treatment, and to improve survival. Furthermore, research on inexpensive biomarkers for asymptomatic disease detection, the introduction of diagnostic imaging tools that utilise artificial intelligence to compensate for inadequate human resources and improving clinical integration across all levels of the healthcare system are essential.
Authors: Linda Birt; Nicky Hall; Jon Emery; Jon Banks; Katie Mills; Margaret Johnson; Willie Hamilton; Fiona M Walter Journal: BMJ Open Respir Res Date: 2014-12-11
Authors: Ghassan B Hamra; Neela Guha; Aaron Cohen; Francine Laden; Ole Raaschou-Nielsen; Jonathan M Samet; Paolo Vineis; Francesco Forastiere; Paulo Saldiva; Takashi Yorifuji; Dana Loomis Journal: Environ Health Perspect Date: 2014-06-06 Impact factor: 9.031
Authors: Cherie P Erkmen; Ryan F Moore; Clifford Belden; Verdi DiSesa; Larry R Kaiser; Grace X Ma; Anuradha Paranjape Journal: Int J Cancer Oncol Date: 2017-05-17
Authors: Anna J Dare; Gregory C Knapp; Anya Romanoff; Olalekan Olasehinde; Olusola C Famurewa; Akinwumi O Komolafe; Samuel Olatoke; Aba Katung; Olusegun I Alatise; T Peter Kingham Journal: Cancer Prev Res (Phila) Date: 2021-09-10